BioInvent to Present Phase 1 Clinical Data for BI-1910, a TNFR2 Agonist for the Treatment of Solid Tumors, at SITC

• As previously reported, the single agent dose escalation of BI-1910 in the Phase 1 study was completed without any notable adverse events

• Updated clinical data will be presented at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting to be held November 5-9, 2025, at National Harbor, MD (USA)

LUND, SE / ACCESS Newswire / October 3, 2025 / BioInvent International AB ("BioInvent") (STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, will present a poster with data from its trial of BI-1910 at the upcoming SITC Annual Meeting. The abstract title, which was released today, is "Preliminary Phase 1 results of clinical trial investigating BI-1910, a Tumor Necrosis Factor Receptor 2 (TNFR2) agonist in solid cancer tumor patients."

BI-1910 is part of BioInvent's tumor-associated regulatory T cells (Treg)-targeting program, where currently the most advanced program, the Phase 2 program BI-1808, has been prioritized. As announced in August of this year, following a comprehensive strategic review - BioInvent decided to concentrate on advancing BI-1808 (as well as BI-1206, an FcyRIIB-blocking antibody). As part of this review, BioInvent is pausing the development of BI-1910.

TNFR2 is particularly upregulated on Tregs of the tumor microenvironment and has been shown to be important for tumor expansion and survival, representing a new and promising target for cancer immunotherapy.

Poster details:
Title: Preliminary Phase 1 results of clinical trial investigating BI-1910, a Tumor Necrosis Factor Receptor 2 (TNFR2) agonist in solid cancer tumor patients.
Abstract number: 581
Date: November 7-8, 2025
Authors: Hernandez T., Doger B., Yachnin J., Staahl Rorberg K., Moreno I., Carneiro A., Falcon Gonzalez A., Holmkvist P., Karlsson I., Lindahl D., Meller M., Mårtensson L., Schoenborn-Kellenberger O., Sundstedt A., Teige I., Piliuhin D., Vaapil M., Wallin J., Frendéus B., McAllister A.

The abstract will be published in the Journal for ImmunoTherapy of Cancer ( JITC ) Abstract Supplement. A link to the supplement will be posted on the SITC website on November 4, 2025.

###

BI-1910 Phase 1/2a Clinical Trial (NCT06205706)
During this part of the Phase 1/2a study the safety, tolerability, and potential signs of efficacy of BI-1910 as a single agent were evaluated in patients with advanced solid tumors.